NCT05615142View on ClinicalTrials.gov

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2026

Conditions
NSCLCLow Dose RadiotherapyStereotactic Body RadiotherapyPD-1 Inhibitor
Interventions
RADIATION

Low Dose Radiotherapy

LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 6 Gy/3f with conventional external beam radiation.

RADIATION

stereotactic body radiation therapy

Partial SBRT at dose escalation levels: 10 Gy/1f, 20 Gy/2f, 30 Gy/3f.

DRUG

PD-1 Inhibitors

Patients will receive treatment with PD-1 inhibitor (dose as recommended in the instruction manual) every 3 weeks for a maximum of 48 months.

Trial Locations (1)

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan University

OTHER